Open Access

Myoferlin expression in non-small cell lung cancer: Prognostic role and correlation with VEGFR-2 expression

  • Authors:
    • Dae Hyun Song
    • Gyung Hyuck Ko
    • Jeong Hee Lee
    • Jong Sil Lee
    • Gyeong‑Won Lee
    • Hyeon Cheol Kim
    • Jung Wook Yang
    • Rok Won Heo
    • Gu Seob Roh
    • Sun‑Young Han
    • Dong Chul Kim
  • View Affiliations

  • Published online on: December 2, 2015     https://doi.org/10.3892/ol.2015.3988
  • Pages: 998-1006
  • Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Myoferlin is a protein that is associated with cellular repair following injury. The expression of myoferlin in breast cancer and pancreatic adenocarcinoma has been reported to correlate with tumor invasiveness, epithelial to mesenchymal transition and an adverse prognosis. In the present study, myoferlin expression was investigated in non‑small cell lung carcinoma (NSCLC), along with its association with patient prognosis and the expression of a number of other proteins. A total of 148 patients exhibiting NSCLC were enrolled in the present study. The survival data of all patients was examined, and myoferlin, vascular endothelial growth factor receptor‑2 (VEGFR‑2), epidermal growth factor receptor, E‑cadherin, β‑catenin, thyroid transcription factor‑1 and tumor protein p63 expression was investigated via immunohistochemical staining of tissue microarrays. Myoferlin expression was detected in the cytoplasm of 75/148 (50.7%) of the NSCLC cases. In the adenocarcinoma cases, myoferlin‑positive patients possessed a poorer prognosis (odds ratio, 2.94; P=0.339). In the squamous cell carcinoma cases, myoferlin expression was significantly associated with VEGFR‑2 expression (P=0.001). Immunohistochemical staining for VEGFR‑2 and myoferlin expression indicated similar features and cytoplasmic staining in tumor cells. As VEGFR‑2 is a significant target for novel anticancer therapies, it is anticipated that myoferlin may also possess the potential to become a novel clinical target for the treatment of NSCLC.
View Figures
View References

Related Articles

Journal Cover

February-2016
Volume 11 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Song DH, Ko GH, Lee JH, Lee JS, Lee GW, Kim HC, Yang JW, Heo RW, Roh GS, Han SY, Han SY, et al: Myoferlin expression in non-small cell lung cancer: Prognostic role and correlation with VEGFR-2 expression. Oncol Lett 11: 998-1006, 2016
APA
Song, D.H., Ko, G.H., Lee, J.H., Lee, J.S., Lee, G., Kim, H.C. ... Kim, D.C. (2016). Myoferlin expression in non-small cell lung cancer: Prognostic role and correlation with VEGFR-2 expression. Oncology Letters, 11, 998-1006. https://doi.org/10.3892/ol.2015.3988
MLA
Song, D. H., Ko, G. H., Lee, J. H., Lee, J. S., Lee, G., Kim, H. C., Yang, J. W., Heo, R. W., Roh, G. S., Han, S., Kim, D. C."Myoferlin expression in non-small cell lung cancer: Prognostic role and correlation with VEGFR-2 expression". Oncology Letters 11.2 (2016): 998-1006.
Chicago
Song, D. H., Ko, G. H., Lee, J. H., Lee, J. S., Lee, G., Kim, H. C., Yang, J. W., Heo, R. W., Roh, G. S., Han, S., Kim, D. C."Myoferlin expression in non-small cell lung cancer: Prognostic role and correlation with VEGFR-2 expression". Oncology Letters 11, no. 2 (2016): 998-1006. https://doi.org/10.3892/ol.2015.3988